Carson William H. — SEC insider filings
SEC reporting owner CIK 1824280. 32 insider filings on record with FilingPulse; latest filed 2026-11-20.
Transaction summary — filings shown
Covers all 32 filings on record, filed 2020-09-11 to 2026-11-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 19 legs across 19 filings — 112,405 shares, $495,806 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: purchase of 34,000 shares @ $3.58 ($121,720) in Annexon, Inc., filed 2026-11-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | Director | 26 | 19 legs · 112,405 sh · $495,806 | — | 7 |
| Decibel Therapeutics, Inc. (DBTX) | Director | 4 | — | — | 8 |
| Prevail Therapeutics Inc. (PRVL) | Director | 2 | — | — | 2 |
Insider filings — Carson William H.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-20 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 34,000 @ $3.58 | EDGAR |
| 2026-06-15 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 8,000 @ $5.78 | EDGAR |
| 2026-04-14 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 8,000 @ $6.20 | EDGAR |
| 2026-03-12 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 8,000 @ $5.67 | EDGAR |
| 2026-01-02 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 4,115 @ $5.02 | EDGAR |
| 2025-12-03 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 4,115 @ $4.47 | EDGAR |
| 2025-10-31 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 4,115 @ $3.17 | EDGAR |
| 2025-10-02 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 4,115 @ $3.05 | EDGAR |
| 2025-09-04 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 4,115 @ $2.09 | EDGAR |
| 2025-08-01 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 4,115 @ $2.43 | EDGAR |
| 2025-07-01 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 4,115 @ $2.46 | EDGAR |
| 2025-06-09 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 3,200 @ $5.33 | EDGAR |
| 2024-10-02 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 3,200 @ $5.97 | EDGAR |
| 2024-09-04 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 3,200 @ $5.48 | EDGAR |
| 2024-08-05 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 3,200 @ $6.24 | EDGAR |
| 2024-07-02 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 3,200 @ $5 | EDGAR |
| 2024-06-07 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 3,200 @ $4.83 | EDGAR |
| 2024-05-03 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 3,200 @ $4.68 | EDGAR |
| 2024-04-10 | 4 | Annexon, Inc. (ANNX) | Purchase (P): 3,200 @ $6.07 | EDGAR |
| 2023-09-25 | 4 | Decibel Therapeutics, Inc. (DBTX) | Disposition to issuer (D): 5,000 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2023-06-14 | 4 | Decibel Therapeutics, Inc. (DBTX) | Grant/award (A): 5,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | Decibel Therapeutics, Inc. (DBTX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-03 | 4 | Decibel Therapeutics, Inc. (DBTX) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-02-08 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Prevail Therapeutics Inc. (PRVL) | Disposition to issuer (D): 34,000 (derivative) @ $0 | EDGAR |
| 2020-09-11 | 4 | Prevail Therapeutics Inc. (PRVL) | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1824280 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs